Last edition
News about "Dr Krishna Prasad Chigurupati"
Granules Gains First-to-File Status for Ruxolitinib ER Tablets
Granules India has filed a Paragraph IV certification for Ruxolitinib Extended-Release (ER) Tablets, and may qualify for first-to-file status.
Dr. Krishna Prasad Chigurupati | 09/10/2026 | By News Bureau | 226
Granules India secures Sole First-to-File ANDA status for Sodium Oxybate Extended-Release for Oral Suspension, strengthening its US complex generics portfolio.
Dr. Krishna Prasad Chigurupati | 06/07/2026 | By Akanki | 234
Granules Pharmaceuticals Secures US FDA Tentative Approval for gDYANAVEL XR
The tentative approval clears a key regulatory milestone for Granules Pharmaceuticals’ Abbreviated New Drug Application (ANDA), which the US FDA has determined to be eligible for 180-day market exclusivity.
Dr Krishna Prasad Chigurupati | 09/01/2026 | By News Bureau | 203
Granules Pharma Gets US FDA Tentative Approval for Generic ADZENYS XR-ODT
Granules Pharmaceuticals Inc has received tentative approval from the US FDA for its generic version of Amphetamine Extended-Release Orally Disintegrating Tablets (ADZENYS XR-ODT), which will be manufactured at the company’s US-based facility in Chantilly, Virginia.
Dr Krishna Prasad Chigurupati | 22/12/2025 | By News Bureau | 236
Granules India and NIPER SAS Nagar Open Centre for Sustainable Pharma Solutions
Granules India and NIPER collaborate to open the Dr Chigurupati Centre of Excellence for empowering researchers with advanced facilities towards eco-friendly pharmaceutical manufacturing.
Dr Krishna Prasad Chigurupati | 05/09/2025 | By Dineshwori | 325
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy